Live Updates: U.S. recommends “pause” for Johnson & Johnson COVID vaccine to review blood clot cases – CBS News

The Centers for Disease Control showed in an alert Tuesday that the Johnson & & Johnson vaccine could resume as quickly as Wednesday. The alert came after a chaotic day when the Food and Drug Administration advised there be a “time out” for the vaccine, leading practically every state to halt usage of the single-dose shot.
The CDCs Advisory Committee on Immunization Practices will assemble Wednesday for an emergency situation session, with a vote arranged on “upgraded recommendations for usage” before the group adjourns at 4:30 p.m. ET.
Dr. Anthony Fauci, President Bidens primary medical adviser, informed “CBS Evening News” anchor Norah ODonnell on Tuesday night that it appeared that the unfavorable impact occurred within 6 to 13 days, and “so if youve had it a month or 2 ago, I think you really do not need to worry about anything.”
Fauci stressed that the chance of these unfavorable adverse effects is “less than 1 in a million,” however he said to be alert to the signs such as severe headache, some problem in movement– such as in a neurological kind of a situation– or some chest discomfort and trouble breathing.
Since Monday, more than 6.8 million dosages of the Johnson & & Johnson vaccine had actually been administered throughout the U.S., a small portion of the general 190 million COVID vaccine shots provided nationwide– many of them from Pfizer and Moderna.
The White House said Tuesday that the pause “will not have a substantial impact” on the nationwide vaccine plan. President Biden assured Americans that he had made certain the U.S. has enough vaccine doses for all American adults from Pfizer and Moderna alone..
The handful of cases the FDA and CDC are examining occurred in women and involved a blood embolism called cerebral venous sinus apoplexy, which was seen together with low levels of blood platelets, according to their statement. Symptoms were seen 6 to 13 days after vaccination in the women, who were in between the ages of 18 and 48.
” Treatment of this particular type of embolism is different from the treatment that may normally be administered. Normally, an anticoagulant drug called heparin is utilized to deal with embolism. In this setting, administration of heparin might threaten, and alternative treatments need to be offered,” they stated.
The firms said the “unfavorable events” appear to be exceptionally rare, however that the time out is essential so that health care service providers can be warned of the responses and appropriately acknowledge and handle the cases, offered the distinct treatment needed.
Ed OKeefe contributed to this report.

Leave a Reply

Your email address will not be published. Required fields are marked *